Scholar Rock Holding Corporation
NASDAQ:SRRKBiotechnology
+$0.49 today
- Market cap
- $5.86B
- Beta
- 0.69
- P/E (TTM)
- -14.8
- EPS (TTM)
- -$3.21
Volume 2.77M
Average 1.46M
SRRK Sales of Investments
Cash received from selling or redeeming investments.
Scholar Rock Holding CorporationNASDAQ: SRRK
Sales of Investments · Q3 FY2026 · quarter ended Sep 2026
Sales of investments declines year over year
Q3 FY2026 sales of investments of $12M fell 84.7% year over year, behind the -63.0% change in trailing-twelve-month sales of investments. Sequentially, it fell 68.0% from the prior quarter. Over 3 fiscal years it compounded at +34.6% a year.
Context
- Sales of investments increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -84.7% toward the trailing-twelve-month pace of -63.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 317.3M USD
- Year-over-year change
- +46.1%
- 4-year CAGR
- +12.2%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 317.3M | +46.1% |
| FY2024 | 2024-12-31 | 217.2M | -34.6% |
| FY2023 | 2023-12-31 | 332M | +155.4% |
| FY2022 | 2022-12-31 | 130M | -35.0% |
| FY2021 | 2021-12-31 | 200M | — |
Sales of Investments vs competitors
How SRRK compares with its peers on the latest reported figures
- SRRK's LTM Sep 2026 sales of investments of $108.5M is the 8th largest of the 11 companies compared; the peer median is $229.34M.
- Its year-over-year change of -63.0% is the 8th highest of 10, against a peer median of +17.6%.
- Sales of investments amounts to 19035.1% of revenue for SRRK, versus a peer median of 189.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.82B | +4.9% | +19.7% | 189.3% | |
| LTM Jun 2026 | $1.34B | +87.1% | +18.2% | 132.6% | |
| LTM Jun 2026 | $818.71M | +17.6% | -11.0% | 524.7% | |
| LTM Sep 2026 | $818.03M | +32.8% | +30.6% | — | |
| LTM Mar 2026 | $294M | -81.2% | -20.2% | 13.5% | |
| LTM Mar 2026 | $164.68M | +98.9% | -5.0% | 513.3% | |
| LTM Jun 2026 | $157.88M | -17.7% | -6.6% | — | |
| LTM Sep 2026 | $108.5M | -63.0% | +34.6% | 19035.1% | |
| LTM Jun 2026 | $50.6M | +26.5% | -72.6% | 7.1% | |
| LTM Mar 2026 | $47.5M | — | — | 237.5% | |
| LTM Sep 2026 | $11.04M | -102.4% | +29.6% | — | |
| Peer median (excluding SRRK) | $229.34M | +17.6% | -5.0% | 189.3% | |
Competitors are the stored peer set for SRRK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (131.8M) | (134.5M) | (165.79M) | (246.29M) | (377.94M) |
| Depreciation & Amortization | 2.63M | 2.99M | 2.84M | 1.94M | 1.66M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 23.15M | 27.7M | 27.14M | 36.63M | 75.6M |
| Change in Working Capital | (28.44M) | (34.39M) | (10.61M) | 6.59M | (1.05M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.02M | (251K) | (529K) | 6.63M | 208K |
| Other Working Capital | (29.46M) | (34.14M) | (10.09M) | (36K) | (1.26M) |
| Other Non-Cash Items | 7.67M | 5.51M | 1.19M | 186K | 1.7M |
| Operating Cash Flow | (126.79M) | (132.69M) | (145.23M) | (200.95M) | (300.04M) |
| Capital Expenditures | (5.25M) | (1.06M) | (71K) | (98K) | (602K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (60.44M) | (300.63M) | (290.8M) | (293.16M) | (98.01M) |
| Sales of Investments | 200M | 130M | 332M | 217.2M | 317.3M |
| Other Investing Activities | 0 | 0 | 13K | 0 | 0 |
| Investing Cash Flow | 134.32M | (171.7M) | 41.14M | (76.06M) | 218.69M |
| Debt Repayment | 24.98M | (975K) | 0 | 0 | 49.14M |
| Common Stock Issued | 13.1M | 195.32M | 97.71M | 324.41M | 179.26M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 6.87M | 492K | 4.87M | 28.61M | 0 |
| Financing Cash Flow | 44.95M | 194.83M | 102.57M | 353.03M | 228.4M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (2K) |
| Net Change in Cash | 52.48M | (109.56M) | (1.51M) | 76.02M | 147.05M |
| Free Cash Flow | (132.04M) | (133.76M) | (145.3M) | (201.05M) | (300.64M) |
Scholar Rock Holding Corporation
NASDAQ:SRRK
Intrinsic Alpha fair value
Locked
Current Price
$48.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.